This article is more than 5 years old. Information may no longer be current.
Corticosteroid eye drop may treat diffuse DME
Treatment with corticosteroid eye drops improved visual acuity and reduced retinal thickness in patients with diffuse diabetic macular edema, a study found.
The nonrandomized, prospective clinical study examined 19 eyes of 15 subjects with diffuse DME who had not received treatment for the previous 3 months. Study participants were treated with difluprednate ophthalmic emulsion 0.05% four times each day for 1 month, then twice each day for the subsequent 2 months.
A control group included 22 eyes of 11 subjects with DME who had undergone the steroid responder test.
In the treatment group, baseline mean retinal thickness was 461.1 ± 109.9 μm, and mean logMAR visual acuity was 0.38 ± 0.25.
Mean retinal thickness decreased to 372.1 ± 70.0 μm (P = .006) and mean visual acuity improved to 0.29 ± 0.25 (P = .30) after 1 month of treatment.
There were no significant changes in visual acuity or retinal thickness in the control group.